Case Reports
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
https://doi.org/10.4084/MJHID.2025.013

Leukemia cutis in a patient with acute myeloid leukemia undergoing Azacitidine-Venetoclax: case presentation and review of the literature

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: December 5, 2024
Accepted: January 27, 2025
Published: February 27, 2025
945
Views
980
Downloads
92
HTML
Acute Myeloid leukemia, Venetoclax, Hypomethylating agents, extramedullary localization

Authors

Elisa Buzzatti
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Cristina Mauro
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Caterina Botti
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Roberta Presicci
Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Giovangiacinto Paterno
UOSD Mieloproliferative, Policlinico Tor Vergata, Rome, Italy.
Raffaele Palmieri
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Italy.
Carmelo Gurnari
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Italy.
Flavia Mallegni
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Italy.
Elisa Meddi
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Italy.
Federico Moretti
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Italy.
Lucia Cardillo
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Italy.
Valeria Mezzanotte
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Italy.
Kristian Taka
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Italy.
Lucrezia De Marchi
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Italy.
Luca Maurillo
UOSD Mieloproliferative, Policlinico Tor Vergata, Rome, Italy.
Francesco Buccisano
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Adriano Venditti
Adriano.Venditti@uniroma2.it
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.
Maria Ilaria Del Principe
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy.

Leukemia cutis (LC) is a rare extramedullary localization of acute myeloid leukemia (AML). LC management generally relies on AML treatment, namely intensive chemotherapy (IC). In frail patients with LC, viable options are hypomethylating agents (HMA) associated with Venetoclax, but literature about their use is scarce. Here, we report our experience and a short review of the previous cases of LC treated with HMA plus Venetoclax to underline the efficacy of such treatment in LC patients unsuitable for IC.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite



“Leukemia cutis in a patient with acute myeloid leukemia undergoing Azacitidine-Venetoclax: case presentation and review of the literature” (2025) Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025013. doi:10.4084/MJHID.2025.013.
Copyright (c) 2025 Elisa Buzzatti, Cristina Mauro, Caterina Botti, Roberta Presicci, Giovangiacinto Paterno, Raffaele Palmieri, Carmelo Gurnari, Flavia Mallegni, Elisa Meddi, Federico Moretti, Lucia Cardillo, Valeria Mezzanotte, Kristian Taka, Lucrezia De Marchi, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.